In-Vitro Diagnostics (IVD) Market Research Report – Forecast to 2027

In-Vitro Diagnostics Market Research Report, By Product & Services (Reagents & Kits, Instruments, Data management software), By Applications (Infectious Diseases, Non-infectious diseases), By End User - Forecast till 2027

ID: MRFR/MED/0659-CR | February, 2021 | Region : Global

In-Vitro Diagnostics Market Overview


Global In-Vitro Diagnostics Market, according to MRFR, is projected to register a CAGR of 8.16% and acquired the value of 102.55 Billion during the forecast period from 2018 to 2023. It is expected that the growing incidence of chronic diseases such as cancer and diabetes, improved understanding of disease diagnosis, and increasing levels of disposable income would help the growth of this sector.

COVID-19 Analysis Of In-Vitro Diagnostics Market


During the COVID-19 pandemic, the value of these items has risen, as individuals prefer simple screening testing that can be done in home care environments. The positive effect of Covid-19 on demand for IVD products can be due to Kist and reagent products having a fast growth rate. The emergence of the Covid-19 pandemic has intensified the need for reagents and kits that provide rapid diagnosis and help combat the lethal effects of the virus.


In-Vitro Diagnostics Market Dynamics


Drivers


Growing Prevalence of Chronic Diseases to Drive Market Growth


Observations of the global health scenario indicate increasing incidences of chronic diseases. Diseases such as tuberculosis, diabetes, cancer, and cardiovascular diseases are growing rapidly in incidence, and the substantial rise in patients suffering from such diseases and a variety of other infectious and non-infectious disease has been highly conducive for the growth of the in-vitro diagnostics market. The market for in-vitro diagnostics has been greatly increased by the growing incidence of these diseases worldwide. In saving millions of lives, prompt and effective diagnosis has been vital; this has directly led to the appreciation of the global demand for IVD. In comparison, in-vitro diagnostics have improved dramatically in recent years, bringing additional testing to existing industry offers. Technology developments have given rise to precision medicine, which is a growing diagnostic practise. It is possible to customise medication and therapeutics to a patient's personal genetic profile using sophisticated medical methods in an attempt to give the patient the highest chance of survival with reduced side effects. It is anticipated that the growing potential of this method of diagnostics will contribute to the proliferation of the global in-vitro diagnostics market.


Opportunities


Growing R&D Investments to Create New Opportunities for Key Players


IVD research has undergone a huge advancement that has improved the attractiveness of in-vitro diagnostics. Pregnancy tests, for example, have also been popular for at-home use, making them incredibly handy. In a related way, with the aid of point-of-care monitoring systems, at-home blood glucose monitors have raised the market for those devices. Due to the rising demand for such technologies, this aspect also suggests opportunities for the industry. In addition, the prospective growth of the IVD sector is highly encouraging in developed countries and is expected to result in market expansion in the coming years.


Restraints


There is currently a lack of a proper in-vitro diagnostic reimbursement scheme that is intended to curtail demand growth.
In-Vitro Diagnostics Market-Segmental Analysis


Global In-Vitro Diagnostics market was segmented in the report on the basis of product & service, technology, application, end-user, and area. Products and services included in the in-vitro market are data management software, reagents & kits, instruments, and services. Due to the growing adoption of point-of-care monitoring, reagents and kits account for the largest market share of 74.8 percent. During the evaluation period, the In-vitro diagnostics market services segment is expected to rise at the fastest CAGR.


The technologies used in the in-vitro diagnostics market are broadly segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, and others. Owing to its capacity to produce quicker outcomes, the growing preference for advanced technology has catapulted the clinical chemistry segment into a leading role. Meanwhile, with the highest CAGR of 6.41 percent during the forecast period, the In-vitro diagnostics market is projected to expand.


In-vitro diagnostics have applications in non-infectious diseases and infectious diseases. In the detection of infectious diseases, IVD is used more often, with a volume of USD 38,685 in 2017. However, during the evaluation period, the non-infectious diseases segment is projected to rise at the fastest CAGR of 9.48 percent.


Laboratories, academic institutions, hospitals, and others include end-users of in-vitro diagnostics. Owing to the fact that a majority of in-vitro diagnostic procedures are carried out in hospital labs, hospitals account for a 39.4 percent share of the market. Meanwhile, during the analysis period, the lab segment is likely to experience the fastest growth at the highest CAGR.


In-Vitro Diagnostics Market Regional Analysis


Four main areas, including the Asia Pacific, the Americas, Europe, and the MEA, have been given a geographical description from the global in-vitro diagnostics market.


Superior Healthcare Infrastructure to Drive Americas growth


More than 39 per cent of the overall in-vitro diagnostics market accounted for the highest share of the Americas. Owing to the concentration of industrialised economies such as the US and Canada, the region is split into North America and South America, with North America becoming the bigger sector. The growing aged population of regions is a key demographic that encourages the growth of the IVD industry. In addition, the North American area has experienced, and continues to experience, a large number of occurrences of chronic diseases that lead to regional market development. Among other reasons, this has contributed to the country gaining a leading role in the global in-vitro diagnostics market.


Expansion of Key players Regional Footprint to Drive Market Growth


Europe has the second biggest economy, and has a growth rate similar to that of the Americas. Several health associations have been working to increase awareness of the region's point-of-care assessments that have promoted business expansion. In addition, it is predicted that rising healthcare budgets and an emphasis on early disease detection will help the region maintain its market place over the forecast period.


APAC to Account as the Fastest-growing Region


The fastest rising market is Asia Pacific (APAC), while the Middle East and Africa (MEA) account for the lowest market share. During the forecast period, both regions are anticipated to observe identical CAGRs. Owing to the prevalence of a massive patient population and a growing appetite for specialised healthcare, APAC is a profitable market. Rising spending on healthcare infrastructure construction is projected to promote business growth. In addition, there are high birthrates in nations such as India and China, which also drives the in-vitro diagnostics market. The MEA area, meanwhile, is important due to the existence of big opportunities in the region.
In-Vitro Diagnostics Market Competitive Landscape


Mergers and Acquisitions to Improve Competitive Standing of Key Players


 Although there are many big players in the in-vitro industry, there are also smaller and medium-sized companies that make their presence known in the market by embracing technical innovations and developments in their products. By releasing goods at a much cheaper price, these tactics are carried out.



  • Abbott Laboratories

  • Bio-Rad Laboratories Inc.

  • Hoffmann-La Roche AG

  • Grifols S.A, bioMérieux S.A

  • DiaSorin S.p.A

  • Ortho Clinical Diagnostics

  • Qiagen N.V.

  • Siemens AG

  • Becton Dickinson and Company

  • Danaher Corporation

  • Thermo Fisher Scientific

  • Sysmex Corporation


Recent Development


December 2020: With its Lumipulse G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test, Fujirebio Diagnostics Inc. attempted to extend the arsenal of AD diagnostics further.


December 2020: -Veracyte, Inc. reported that its Quality Management System (QMS) for the design, production and manufacture of genomic in vitro diagnostic (IVD) tests that help in the diagnosis and prognosis of cancer and other diseases has been granted ISO 13485:2016 certification.


Report Overview


By Product & Services



  • Reagents & Kits

  • Instruments

  • Data management software


By Technology



  • Immunoassay/immunochemistry

  • clinical chemistry

  • Molecular diagnostics

  • Microbiology

  • Hematology


By Application



  • Infectious diseases

  • Non-infectious diseases


By End-User



  • Hospitals

  • Laboratories

  • Academic institutes

The Global In-Vitro Diagnostics Market is projected to register a CAGR 8.16% during the forecast period from 2018 to 2023. This projects above-average growth for the market. In-vitro diagnostics include tests which are performed on tissue, blood or other samples taken from the human body and are used extensively for the testing of a large number of medical problems. Valued at USD 69,284.16 Mn in 2017, the global in-vitro diagnostics report is expected to grow to generate a market value of USD 102,555.24 Mn by the end of 2023.


Observations of the global health scenario indicate increasing incidences of chronic diseases. Diseases such as tuberculosis, diabetes, cancer, and cardiovascular diseases are growing rapidly in incidence, and the substantial rise in patients suffering from such diseases and a variety of other infectious and non-infectious disease has been highly conducive for the growth of the in-vitro diagnostics market. The rising prevalence of these diseases across the globe has substantially increased the demand for in-vitro diagnostics. Timely and efficient diagnosis has been vital in saving millions of lives; this has directly contributed to the appreciation of the global IVD market. Moreover, in-vitro diagnostics has advanced significantly in recent years with new tests being added to the current offerings in the market. Advancements in technology have given rise to personalized medicine which is a growing trend in diagnostics. Using advanced diagnostic techniques, it is possible to tailor treatment and therapeutics to a patients personal genetic profile in an effort to offer the patient the best chance at recovery with minimal side effects. The increasing potential of this type of diagnostics is expected to lead to the proliferation of the global in-vitro diagnostics market.


Presently, there is a lack of a sufficient reimbursement system for in-vitro diagnostics which is expected to restrain market growth. Varying international structures make it challenging to implement effective strategies on a global scale. Notably, IVD technologies have undergone significant development which has increased the appeal of in-vitro diagnostics. For instance, pregnancy tests have now become accessible for at-home use, making them highly convenient. In a similar vein, at-home testing of blood glucose levels with the help of point-of-care testing devices has increased the demand for such devices. This factor also indicates opportunity for the market due to the increasing demand for such technology. Moreover, the imminent growth of the IVD market in developing countries is highly promising and will likely result in market expansion in the coming years.


The global in-vitro diagnostics market, in the report, has been segmented on the basis of product & service, technology, application, end-user, and region. Products and services included in the in-vitro market are reagents & kits, instruments, data management software, and services. Reagents and kits account for a majority market share of 74.8% due to the increasing adoption of point-of-care testing. The services segment is projected to grow at the highest CAGR during the assessment period.


The technology used for in-vitro diagnostics is broadly segmented into clinical chemistry, immunoassay/immunochemistry, molecular diagnostics, hematology, microbiology, and others. The increasing preference for advanced technology due to its ability to provide faster results has catapulted the clinical chemistry segment into a leadership position. Meanwhile, the molecular diagnostics market is expected to grow with the highest CAGR of 6.41% during the forecast period.


In-vitro diagnostics have applications in non-infectious diseases and infectious diseases. IVD is used more commonly in the diagnosis of infectious diseases which valued USD 38,685 in 2017. However, the non-infectious diseases segment is expected to grow at the highest CAGR of 9.48% during the assessment period.


End-users of in-vitro diagnostics include laboratories, academic institutes, hospitals, and others. Hospitals account for a share of 39.4% of the market due to the fact that a majority of in-vitro diagnostic tests are performed in hospital laboratories. Meanwhile, the laboratories segment is likely to witness the fastest growth at the highest CAGR during the review period.


In-Vitro Diagnostics Market Regional Analysis


The Americas account for the largest share of over 39% of the global in-vitro diagnostics market. The region is divided into North America and South America, with North America being the larger market due to the concentration of developed economies such as the US and Canada. The regions increasing aged population is a key demographic which is encouraging the growth of the IVD market. Moreover, the North American region has witnessed and continues to witness high numbers of chronic diseases occurrences which contribute to the growth of the regional market. This among other factors have resulted in the region attaining a leadership position in the global in-vitro diagnostics market.


Europe accounts for the second largest market which has a comparable growth pattern to that of the Americas. Several health organizations have been working toward raising awareness of point-of-care testing in the region which has encouraged market growth. Moreover, increasing healthcare budgets and a focus on the early diagnosis of diseases are expected to help the region retain its market position over the forecast period.


Asia Pacific (APAC) accounts for the fastest growing market, while the Middle East and Africa (MEA) account for the lowest share of the market. Both regions are expected to witness similar CAGRs during the forecast period. The APAC is a lucrative market due to the presence of a considerable patient population and an increasing demand for advanced healthcare. Increasing expenditure on the development of healthcare infrastructure is expected to encourage market growth. Moreover, countries such as India and China have high birthrates which also fuels the demand for in-vitro diagnostics. Meanwhile, the MEA region is significant due to the presence of massive opportunity in the market.


In-Vitro Diagnostics Market Competitive Tracking


Profiling of prominent market players has been included in the report. Eminent market players that have been analyzed include F. Hoffmann-La Roche AG, Abbott Laboratories, Siemens AG, Bio-Rad Laboratories Inc, Qiagen N.V, BioMérieux S.A, Becton Dickinson and Company, DiaSorin S.p.A, Ortho Clinical Diagnostics, Grifols S.A, Danaher Corporation, Sysmex Corporation, and Thermo Fisher Scientific.

1 Report Prologue

2 Market Introduction

2.1 Scope of Study 21

2.2 Research Objective 21

2.3 List of Assumptions 21

2.4 Market Structure 22

3 Research Methodology

3.1 Research Process 24

3.2 Primary Research 25

3.3 Secondary Research 26

3.4 Market Size Estimation 27

3.5 Forecast Model 27

4 Market Dynamics

4.1 Introduction 29

4.2 Drivers 30

4.2.1 Rising prevalence of chronic and infectious diseases 30

4.2.2 Growing awareness of personalized medicine 31

4.2.3 Increasing adoption of point-of-care testing 32

4.2.4 Rising investments in research and development and collaborations between companies and

public organizations 32

4.3 Restraints 33

4.3.1 Unfavorable reimbursement scenario 33

4.3.2 Lack of standardization and transparency 33

4.3.3 Information and interest gap between investors and developers 33

4.4 Opportunities 34

4.4.1 Recent technological advancements have increased the appeal of in-vitro diagnostics 34

4.4.2 Developing economies provide an unserved market for in-vitro diagnostics 34

4.4.3 Growing significance of companion diagnostics 34

5 Market Factor Analysis

5.1 Porters Five Forces Analysis 36

5.1.1 Bargaining Power of Suppliers 36

5.1.2 Bargaining Power of Buyers 37

5.1.3 Threat of New Entrants 37

5.1.4 Threat of Substitutes 37

5.1.5 Intensity of Rivalry 37

5.2 Value Chain Analysis 38

5.2.1 Primary activities 38

5.2.2 Secondary Activities 38

6 In-Vitro Diagnostics Market, By Product & Services

6.1 Introduction 40

6.1.1 Reagents & Kits 41

6.1.2 Instruments 41

6.1.3 Data Management Software 41

7 In-Vitro Diagnostics Market, By Technology

7.1 Introduction 44

7.1.1 Immunoassay/Immunochemistry 45

7.1.2 Clinical Chemistry 47

7.1.3 Molecular Diagnostics 47

7.1.4 Microbiology 48

7.1.5 Hematology 48

8 In-Vitro Diagnostics Market, By Application

8.1 Introduction 50

8.1.1 Infectious Diseases 51

8.1.2 Non-Infectious Diseases 51

9 In-Vitro Diagnostics Market, By End User

9.1 Introduction 54

9.1.1 Hospitals 55

9.1.2 Laboratories 55

9.1.3 Academic Institutes 55

10 Global In-Vitro Diagnostics Market, By Region

10.1 Introduction 57

10.2 Americas 58

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.2.1 North America 62

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.2.1.1 US 66

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.2.1.2 Canada 69

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.2.2 South America 72

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.3 Europe 76

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User


10.4 Western Europe 80

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.4.1 Germany 84

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.4.2 UK 88

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.4.3 France 91

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.4.4 Spain 95

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.4.5 Italy 98

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.4.6 Rest of Western Europe 101

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.4.7 Eastern Europe 105

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.5 Asia-Pacific 109

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.5.1 China 113

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.5.2 Japan 116

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.5.3 India 119

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.5.4 Australia 122

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.5.5 Rest of Asia-Pacific 126

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.6 Middle East & Africa 130

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.6.1 Middle East 134

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

10.6.2 Africa 138

In-Vitro Diagnostics Market, By Product & Services

In-Vitro Diagnostics Market, By Technology

In-Vitro Diagnostics Market, By Application

In-Vitro Diagnostics Market, By End User

11 Competitive Landscape

11.1 Competitive Scenario 143

11.1.1 Introduction 143

11.2 Company Market Share Analysis 144

11.2.1 Introduction 144

11.3 Key Developments 145

12 Company Profile

12.1 F. Hoffmann-La Roche AG 148

12.1.1 Company Overview 148

12.1.2 Financial Overview 148

12.1.3 Products & Services Offered 149

12.1.4 Key Developments 149

12.1.5 SWOT Analysis 149

12.1.6 Key Strategy 149

12.2 Abbott Laboratories 150

12.2.1 Company Overview 150

12.2.2 Financial Overview 150

12.2.3 Products & Services Offered 151

12.2.4 Key Developments 151

12.2.5 SWOT Analysis 151

12.2.6 Key Strategy 151

12.3 Siemens AG 152

12.3.1 Company Overview 152

12.3.2 Financial Overview 152

12.3.3 Products & Services Offered 153

12.3.4 Key Developments 153

12.3.5 SWOT Analysis 153

12.3.6 Key Strategy 153

12.4 Bio-Rad Laboratories, Inc. 154

12.4.1 Company Overview 154

12.4.2 Financial Overview 154

12.4.3 Products & Services Offered 155

12.4.4 Key Developments 155

12.4.5 SWOT Analysis 155

12.4.6 Key Strategy 155

12.5 Qiagen N.V. 156

12.5.1 Company Overview 156

12.5.2 Financial Overview 156

12.5.3 Products & Services Offered 157

12.5.4 Key Developments 157

12.5.5 SWOT Analysis 157

12.5.6 Key strategy 157

12.6 BioMérieux S.A. 158

12.6.1 Company Overview 158

12.6.2 Financial Overview 158

12.6.3 Products & Services Offered 159

12.6.4 Key Developments 159

12.6.5 SWOT Analysis 159

12.6.6 Key Strategy 159

12.7 Becton, Dickinson and Company 160

12.7.1 Company Overview 160

12.7.2 Financial Overview 160

12.7.3 Products & Services Offered 161

12.7.4 Key Developments 161

12.7.5 SWOT Analysis 161

12.7.6 Key Strategy 161

12.8 DiaSorin S.p.A 162

12.8.1 Company Overview 162

12.8.2 Financial Overview 162

12.8.3 Products & Services Offered 163

12.8.4 Key Developments 163

12.8.5 SWOT Analysis 163

12.8.6 Key Strategy 163

12.9 Ortho Clinical Diagnostics (Part of Johnson & Johnson Services Inc.) 164

12.9.1 Company Overview 164

12.9.2 Financial Overview 164

12.9.3 Products & Services Offered 165

12.9.4 Key Developments 165

12.9.5 SWOT Analysis 165

12.9.6 Key Strategy 165

12.10 Grifols S.A. 166

12.10.1 Company Overview 166

12.10.2 Financial Overview 166

12.10.3 Products & Services Offered 167

12.10.4 Key Developments 167

12.10.5 SWOT Analysis 167

12.10.6 Key Strategy 167

12.11 Danaher Corporation 168

12.11.1 Company Overview 168

12.11.2 Financial Overview 168

12.11.3 Products & Services Offered 169

12.11.4 Key Developments 169

12.11.5 SWOT Analysis 170

12.11.6 Key Strategy 170

12.12 Sysmex Corporation 171

12.12.1 Company Overview 171

12.12.2 Financial Overview 171

12.12.3 Products & Services Offered 172

12.12.4 Key Developments 172

12.12.5 SWOT Analysis 172

12.12.6 Key Strategy 172

12.13 Thermo Fisher Scientific 173

12.13.1 Company Overview 173

12.13.2 Financial Overview 173

12.13.3 Products & Services Offered 174

12.13.4 Key Developments 174

12.13.5 SWOT Analysis 174

12.13.6 Key Strategy 175

13 Appendix

13.1 Discussion Blue Print 177

14 List of Tables

TABLE 1 MARKET SYNOPSIS 19

TABLE 2 LIST OF ASSUMPTIONS 21

TABLE 3 PERSONALIZED THERAPY AUTHORIZED IN GERMANY 31

TABLE 4 GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 40

TABLE 5 GLOBAL IN-VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION 2020-2027 (USD MILLION) 41

TABLE 6 GLOBAL IN-VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION 2020-2027 (USD MILLION) 41

TABLE 7 GLOBAL IN-VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE, BY REGION 2020-2027 (USD MILLION) 41

TABLE 8 GLOBAL IN-VITRO DIAGNOSTICS MARKET FOR SERVICES, BY REGION 2020-2027 (USD MILLION) 42

TABLE 9 GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 45

TABLE 10 GLOBAL IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 45

TABLE 11 GLOBAL IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE,

2020-2027 (USD MILLION) 46

TABLE 12 GLOBAL IN-VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY REGION 2020-2027 (USD MILLION) 46

TABLE 13 GLOBAL IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 47

TABLE 14 GLOBAL IN-VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY REGION 2020-2027 (USD MILLION) 47

TABLE 15 GLOBAL IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 47

TABLE 16 GLOBAL IN-VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION 2020-2027 (USD MILLION) 48

TABLE 17 GLOBAL IN-VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY REGION 2020-2027 (USD MILLION) 48

TABLE 18 GLOBAL IN-VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY REGION 2020-2027 (USD MILLION) 48

TABLE 19 GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 50

TABLE 20 GLOBAL IN-VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION 2020-2027 (USD MILLION) 51

TABLE 21 GLOBAL IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 51

TABLE 22 GLOBAL IN-VITRO DIAGNOSTICS MARKET FOR NON-INFECTIOUS DISEASES, BY REGION 2020-2027 (USD MILLION) 52

TABLE 23 GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 54

TABLE 24 GLOBAL IN-VITRO DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION 2020-2027 (USD MILLION) 55

TABLE 25 GLOBAL IN-VITRO DIAGNOSTICS MARKET FOR LABORATORIES, BY REGION 2020-2027 (USD MILLION) 55

TABLE 26 GLOBAL IN-VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY REGION 2020-2027 (USD MILLION) 55

TABLE 27 GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY REGION 2020-2027 (USD MILLION) 57

TABLE 28 AMERICAS IN-VITRO DIAGNOSTICS MARKET, BY REGION 2020-2027 (USD MILLION) 58

TABLE 29 AMERICAS IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 59

TABLE 30 AMERICAS IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 59

TABLE 31 AMERICAS IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 59

TABLE 32 AMERICAS IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE,

2020-2027 (USD MILLION) 60

TABLE 33 AMERICAS IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 60

TABLE 34 AMERICAS IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 60

TABLE 35 AMERICAS IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 61

TABLE 36 AMERICAS IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 61

TABLE 37 AMERICAS IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 61

TABLE 38 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY 2020-2027 (USD MILLION) 62

TABLE 39 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 62

TABLE 40 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 63

TABLE 41 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE,

2020-2027 (USD MILLION) 63

TABLE 42 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE,

2020-2027 (USD MILLION) 63

TABLE 43 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 64

TABLE 44 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 64

TABLE 45 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 64

TABLE 46 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 65

TABLE 47 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 65

TABLE 48 US IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 66

TABLE 49 US IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 66

TABLE 50 US IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 66

TABLE 51 US IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE, 2020-2027 (USD MILLION) 67

TABLE 52 US IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 67

TABLE 53 US IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 67

TABLE 54 US IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 68

TABLE 55 US IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 68

TABLE 56 US IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 68

TABLE 57 CANADA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 69

TABLE 58 CANADA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 69

TABLE 59 CANADA IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 69

TABLE 60 CANADA IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE,

2020-2027 (USD MILLION) 70

TABLE 61 CANADA IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 70

TABLE 62 CANADA IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 70

TABLE 63 CANADA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 71

TABLE 64 CANADA IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 71

TABLE 65 CANADA IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 71

TABLE 66 SOUTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 72

TABLE 67 SOUTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 72

TABLE 68 SOUTH AMERICA IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE,

2020-2027 (USD MILLION) 73

TABLE 69 SOUTH AMERICA IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE,

2020-2027 (USD MILLION) 73

TABLE 70 SOUTH AMERICA IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 74

TABLE 71 SOUTH AMERICA IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 74

TABLE 72 SOUTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 74

TABLE 73 SOUTH AMERICA IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 75

TABLE 74 SOUTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 75

TABLE 75 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY REGION 2020-2027 (USD MILLION) 76

TABLE 76 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 77

TABLE 77 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 77

TABLE 78 EUROPE IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 77

TABLE 79 EUROPE IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE,

2020-2027 (USD MILLION) 78

TABLE 80 EUROPE IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 78

TABLE 81 EUROPE IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 78

TABLE 82 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 79

TABLE 83 EUROPE IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 79

TABLE 84 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 79

TABLE 85 WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY 2020-2027 (USD MILLION) 80

TABLE 86 WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 80

TABLE 87 WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 81

TABLE 88 WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE,

2020-2027 (USD MILLION) 81

TABLE 89 WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE,

2020-2027 (USD MILLION) 81

TABLE 90 WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 82

TABLE 91 WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 82

TABLE 92 WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 82

TABLE 93 WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 83

TABLE 94 WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 83

TABLE 95 GERMANY IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 84

TABLE 96 GERMANY IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 84

TABLE 97 GERMANY IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 85

TABLE 98 GERMANY IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE,

2020-2027 (USD MILLION) 85

TABLE 99 GERMANY IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 86

TABLE 100 GERMANY IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 86

TABLE 101 GERMANY IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 86

TABLE 102 GERMANY IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 87

TABLE 103 GERMANY IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 87

TABLE 104 UK IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 88

TABLE 105 UK IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 88

TABLE 106 UK IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 88

TABLE 107 UK IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE, 2020-2027 (USD MILLION) 89

TABLE 108 UK IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 89

TABLE 109 UK IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 89

TABLE 110 UK IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 90

TABLE 111 UK IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 90

TABLE 112 UK IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 90

TABLE 113 FRANCE IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 91

TABLE 114 FRANCE IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 91

TABLE 115 FRANCE IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 92

TABLE 116 FRANCE IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE,

2020-2027 (USD MILLION) 92

TABLE 117 FRANCE IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 93

TABLE 118 FRANCE IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 93

TABLE 119 FRANCE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 93

TABLE 120 FRANCE IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 94

TABLE 121 FRANCE IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 94

TABLE 122 SPAIN IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 95

TABLE 123 SPAIN IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 95

TABLE 124 SPAIN IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 95

TABLE 125 SPAIN IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE, 2020-2027 (USD MILLION) 96

TABLE 126 SPAIN IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 96

TABLE 127 SPAIN IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 96

TABLE 128 SPAIN IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 97

TABLE 129 SPAIN IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 97

TABLE 130 SPAIN IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 97

TABLE 131 ITALY IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 98

TABLE 132 ITALY IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 98

TABLE 133 ITALY IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 98

TABLE 134 ITALY IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE, 2020-2027 (USD MILLION) 99

TABLE 135 ITALY IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 99

TABLE 136 ITALY IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 99

TABLE 137 ITALY IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 100

TABLE 138 ITALY IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 100

TABLE 139 ITALY IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 100

TABLE 140 REST OF WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 101

TABLE 141 REST OF WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 101

TABLE 142 REST OF WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE,

2020-2027 (USD MILLION) 102

TABLE 143 REST OF WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE,

2020-2027 (USD MILLION) 102

TABLE 144 REST OF WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 103

TABLE 145 REST OF WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE,

2020-2027 (USD MILLION) 103

TABLE 146 REST OF WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 103

TABLE 147 REST OF WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE

2020-2027 (USD MILLION) 104

TABLE 148 REST OF WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 104

TABLE 149 EASTERN EUROPEIN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 105

TABLE 150 EASTERN EUROPEIN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 105

TABLE 151 EASTERN EUROPEIN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE,

2020-2027 (USD MILLION) 106

TABLE 152 EASTERN EUROPEIN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE,

2020-2027 (USD MILLION) 106

TABLE 153 EASTERN EUROPEIN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 107

TABLE 154 EASTERN EUROPEIN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 107

TABLE 155 EASTERN EUROPEIN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 107

TABLE 156 EASTERN EUROPEIN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 108

TABLE 157 EASTERN EUROPEIN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 108

TABLE 158 ASIA PACFIC IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY 2020-2027 (USD MILLION) 109

TABLE 159 ASIA-PACFIC IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 110

TABLE 160 ASIA-PACFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 110

TABLE 161 ASIA-PACFIC IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 110

TABLE 162 ASIA-PACFIC IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE,

2020-2027 (USD MILLION) 111

TABLE 163 ASIA-PACFIC IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 111

TABLE 164 ASIA-PACFIC IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 111

TABLE 165 ASIA-PACFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 112

TABLE 166 ASIA-PACFIC IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 112

TABLE 167 ASIA-PACFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 112

TABLE 168 CHINA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 113

TABLE 169 CHINA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 113

TABLE 170 CHINA IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 113

TABLE 171 CHINA IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE, 2020-2027 (USD MILLION) 114

TABLE 172 CHINA IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 114

TABLE 173 CHINA IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 114

TABLE 174 CHINA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 115

TABLE 175 CHINA IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 115

TABLE 176 CHINA IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 115

TABLE 177 JAPAN IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 116

TABLE 178 JAPAN IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 116

TABLE 179 JAPAN IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 116

TABLE 180 JAPAN IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE, 2020-2027 (USD MILLION) 117

TABLE 181 JAPAN IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 117

TABLE 182 JAPAN IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 117

TABLE 183 JAPAN IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 118

TABLE 184 JAPAN IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 118

TABLE 185 JAPAN IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 118

TABLE 186 INDIA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 119

TABLE 187 INDIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 119

TABLE 188 INDIA IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 119

TABLE 189 INDIA IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE, 2020-2027 (USD MILLION) 120

TABLE 190 INDIA IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 120

TABLE 191 INDIA IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 120

TABLE 192 INDIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 121

TABLE 193 INDIA IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 121

TABLE 194 INDIA IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 121

TABLE 195 AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 122

TABLE 196 AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 122

TABLE 197 AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 123

TABLE 198 AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE,

2020-2027 (USD MILLION) 123

TABLE 199 AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 124

TABLE 200 AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 124

TABLE 201 AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 124

TABLE 202 AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 125

TABLE 203 AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 125

TABLE 204 REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 126

TABLE 205 REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 126

TABLE 206 REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE,

2020-2027 (USD MILLION) 127

TABLE 207 REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE,

2020-2027 (USD MILLION) 127

TABLE 208 REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 128

TABLE 209 REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 128

TABLE 210 REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 128

TABLE 211 REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 129

TABLE 212 REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 129

TABLE 213 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET, BY REGION 2020-2027 (USD MILLION) 130

TABLE 214 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 131

TABLE 215 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 131

TABLE 216 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE,

2020-2027 (USD MILLION) 131

TABLE 217 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE,

2020-2027 (USD MILLION) 132

TABLE 218 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 132

TABLE 219 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 132

TABLE 220 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 133

TABLE 221 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 133

TABLE 222 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 133

TABLE 223 MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 134

TABLE 224 MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 134

TABLE 225 MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 135

TABLE 226 MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE,

2020-2027 (USD MILLION) 135

TABLE 227 MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 136

TABLE 228 MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 136

TABLE 229 MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 136

TABLE 230 MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 137

TABLE 231 MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 137

TABLE 232 AFRICA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020-2027 (USD MILLION) 138

TABLE 233 AFRICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 138

TABLE 234 AFRICA IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 139

TABLE 235 AFRICA IN-VITRO DIAGNOSTICS MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY BY TYPE, 2020-2027 (USD MILLION) 139

TABLE 236 AFRICA IN-VITRO DIAGNOSTICS MARKET, FOR CLINICAL CHEMISTRY BY TYPE, 2020-2027 (USD MILLION) 140

TABLE 237 AFRICA IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS BY TYPE, 2020-2027 (USD MILLION) 140

TABLE 238 AFRICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020-2027 (USD MILLION) 140

TABLE 239 AFRICA IN-VITRO DIAGNOSTICS MARKET, FOR NON-INFECTIOUS DISEASES BY TYPE 2020-2027 (USD MILLION) 141

TABLE 240 AFRICA IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020-2027 (USD MILLION) 141

TABLE 241 GLOBAL IN-VITRO DIAGNOSTICS MARKET: KEY DEVELOPMENT 145


15 List of Figures

FIGURE 1 GLOBAL IN-VITRO DIAGNOSTICS MARKET: MARKET STRUCTURE 22

FIGURE 2 RESEARCH PROCESS OF MRFR 24

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 27

FIGURE 4 VALUE CHAIN 38

FIGURE 5 GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 2020 & 2027 (USD MILLION) 40

FIGURE 6 GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 2020 & 2027 (USD MILLION) 44

FIGURE 7 GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION 2020 & 2027 (USD MILLION) 50

FIGURE 8 GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY END USER 2020 & 2027 (USD MILLION) 54

FIGURE 9 GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY REGION 2020 & 2027 (USD MILLION) 57

FIGURE 10 AMERICAS IN-VITRO DIAGNOSTICS MARKET, BY REGION COUNTRY 2020 (%) 58

FIGURE 11 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY 2020 (%) 62

FIGURE 12 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY REGION 2020 (%) 76

FIGURE 13 WESTERN EUROPE IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY 2020 (%) 80

FIGURE 14 ASIA PACFIC IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY 2020 & 2027 (USD MILLION) 109

FIGURE 15 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY 2020 (%) 130

FIGURE 16 GLOBAL IN-VITRO DIAGNOSTICS MARKET, COMPETITIVE LANDSCAPE (%) 143

FIGURE 17 GLOBAL IN-VITRO DIAGNOSTICS MARKET, MARKET SHARE ANALYSIS 2020 (%) 144

In Vitro Diagnostics Market

Global In Vitro Diagnostics Market: Competitive Landscape


The prominent players in the global Invitro Diagnostics market are F. Hoffmann-La Roche AG, Danaher Corporation, Abbott Laboratories, Siemens AG, Thermo Fisher Scientific Inc., Becton Dickinson & Company, bioMerieux SA, Sysmex Corporation, Ortho Clinical Diagnostics, Bio-Rad Laboratories, and others.

Hoffmann-La Roche AG is the holds the largest share for the global Invitro Diagnostics market in 2017. F. Hoffmann-La Roche AG is a biotech organization, with genuinely differentiated solutions in oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. The company is dedicated to developing innovative diagnostic tests and medicines. The products offered by the company help in tapping the world’s two third of all the diseases which are either still not treated effectively or not treated at all. Geographically, the company operates in North America, Europe, South America, Africa, and Asia-Oceania.


Danaher Corporation holds second position in terms of market share in the global Invitro Diagnostics market in 2017. The company works in the fields of design, manufacturing, and marketing of industrial and consumer products and operates in five segments, namely, dental, test and measurement, environmental, industrial technologies, and life science and diagnostics.


Abbott Laboratories holds third position in terms of market share in the global Invitro Diagnostics market in 2017. The company operates through four reportable segments, namely, established pharmaceutical products, diagnostic products, nutritional products, and vascular products. Furthermore, the company has two non-reportable segments, namely, diabetes care and medical optics. The diabetes care division of the company is located in California, US and provides blood glucose meters, blood glucose test strips, sensors, data management decision software, and accessories. The company manufacturers its blood glucose test strips at Witney, UK.


Thermo Fisher Scientific Inc. specializes in various biotechnology products such as analytical instruments, laboratory supply chain programs and e-commerce, laboratory equipment, lab services, specialty diagnostics, and others.


Ortho Clinical Diagnostics (Part of Johnson & Johnson Services Inc.) is serving the global clinical laboratory and immunohematology communities across hospitals, hospital networks, blood banks, and labs in more than 120 countries. The company specializes in in-vitro diagnostics, diagnostics, clinical labs, transfusion medicine, and immunohematology.

Hoffmann-La Roche AG, and Danaher Corporation are the major companies for IVD operating on a global scale. The lower market share of Bio-Rad Laboratories can be attributed to fewer products offering, as compared to Sanofi S.A and other major players. Major players such as F. Hoffmann-La Roche AG, Danaher Corporation, Abbott Laboratories, Siemens AG, and Thermofisher Scientific Inc. increase the level of competition in the global IVD monitoring market, as these companies are expected to expand their product portfolios, with the help of other business units, to increase their market share.